Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

CD19 antibody (Biotin)

CD19 Reactivity: Human, Monkey FACS, IF Host: Mouse Monoclonal CVID3-155 Biotin
Catalog No. ABIN6182536
  • Target See all CD19 Antibodies
    CD19 (CD19 Molecule (CD19))
    Reactivity
    • 293
    • 162
    • 48
    • 30
    • 19
    • 10
    • 7
    • 6
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    Human, Monkey
    Host
    • 172
    • 140
    • 47
    • 4
    Mouse
    Clonality
    • 231
    • 128
    • 2
    Monoclonal
    Conjugate
    • 112
    • 22
    • 21
    • 19
    • 16
    • 8
    • 8
    • 8
    • 7
    • 7
    • 7
    • 7
    • 7
    • 7
    • 7
    • 6
    • 6
    • 6
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This CD19 antibody is conjugated to Biotin
    Application
    • 263
    • 116
    • 72
    • 62
    • 60
    • 39
    • 23
    • 20
    • 17
    • 14
    • 14
    • 9
    • 5
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Immunofluorescence (IF)
    Purpose
    Mouse Monoclonal anti-CD19 (CVID3/155), Biotin Conjugate
    Characteristics
    This antibody recognizes a protein of 95 kDa, identified as CD19. CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms. Primary antibodies are available purified, or with a selection of fluorescent CF® dyes and other labels. CF® dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
    Immunogen
    Recombinant human CD19 protein
    Clone
    CVID3-155
    Isotype
    IgG1 kappa
    Top Product
    Discover our top product CD19 Primary Antibody
  • Application Notes
    Immunofluorescence 0.5-1 μg/mL
    • Flow Cytometry 0.5-1 μg/million cells/0.1 mL
    • Optimal dilution for a specific application should be determined by user
    Comment

    Tonsil, lymph node, or spleen

    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    100 μg/mL
    Buffer
    PBS/0.1 % BSA/0.05 % azide
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
  • Target
    CD19 (CD19 Molecule (CD19))
    Alternative Name
    CD19 (CD19 Products)
    Synonyms
    B4 antibody, CVID3 antibody, AW495831 antibody, CD19 antibody, CD19 molecule antibody, CD19 antigen antibody, CD19 antibody, Cd19 antibody
    Background
    B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CVID3, Leu-12, Lymphocyte Surface Antigen, T-cell surface antigen Leu-12
    Molecular Weight
    95 kDa
    Gene ID
    930, 652262
    UniProt
    P15391
    Pathways
    Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
You are here:
Support